Kinetin is a natural substance found in plants. It helps plants grow. It's not something people usually take for health reasons.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Kinetin is a plant hormone from the cytokinin family, a group of natural compounds that control cell growth and division in plants. It is not an FDA-approved medicine for any condition. People mostly encounter it in two very different settings: as an ingredient in anti-aging skin creams and lotions, and as an experimental oral treatment studied in familial dysautonomia. Familial dysautonomia is a rare inherited disorder, found mainly in people of Ashkenazi Jewish descent, that damages the nerves controlling automatic body functions (such as blood pressure, digestion, breathing and tear production) and sensations such as pain and temperature. Kinetin was among the first compounds tested in people to target the genetic cause of this disease. The research is promising but early, and it has not shown that kinetin improves symptoms. In skin care, kinetin is usually found at 0.1% in creams and lotions marketed for sun-damaged or aging skin, and it has been tried in mild rosacea. These products are sold as cosmetics, which do not need FDA approval before going on sale and are not evaluated as treatments.
In familial dysautonomia, a single change in the ELP1 gene (also called IKBKAP) disrupts splicing, the step in which a cell edits a gene's raw message before using it to build a protein. Because a section of the message is often cut out by mistake, nerve cells make too little of a protein they need to develop and survive. In laboratory studies, kinetin helped cells keep that section in, raising production of the normal protein. In a small study of people with the disease, it increased the share of correctly edited messages in white blood cells. Whether the same happens in nerve tissue, and whether it slows the disease, has not been shown. On the skin, kinetin is thought to help the outer layer hold moisture and act as an antioxidant, based mostly on laboratory work. How much this translates into visible changes is uncertain.
Skin products typically contain 0.1% kinetin and in studies were applied to the face twice a day, usually alongside daily sunscreen. Oral kinetin has only been given in research. In familial dysautonomia studies it was taken once a day as capsules (or through a feeding tube) at a high dose calculated from body weight, with weekly clinic visits and blood tests. Kinetin capsules sold online as supplements are not the same as a supervised trial, and there is no established safe or effective dose for anyone to take on their own.
Skin products containing kinetin were generally well tolerated in studies, including in people with sensitive skin from rosacea. As with any new cream, stop using it if it causes redness, burning or a rash. In the oral studies, nausea, diarrhea and headaches were the most common complaints, though some of these were already present before people started kinetin. Blood tests in a 28-day trial picked up modest rises in liver enzymes in three of eight participants, and one person had a drop in platelets (cells that help blood clot) and white blood cells. All of these changes returned to normal after kinetin was stopped. Because these effects are only visible on blood tests, oral use without medical monitoring could miss them.
Very little is known about how oral kinetin interacts with other medicines, and no studies have looked at its safety during pregnancy or breastfeeding. People with liver disease or a low platelet count have particular reason to avoid it outside a supervised study, given the lab changes seen in trials. Anyone with familial dysautonomia who is interested in kinetin or newer kinetin-based compounds should discuss it with their specialist team rather than buying a product independently, since dose, formulation and monitoring all matter and the person's other medicines need to be reviewed.
For skin, results are likely to be modest at best. The main study of 0.1% kinetin cream found slight improvements in texture, color and fine wrinkles after 12 weeks, but it had no comparison group, so some of the change may reflect sunscreen use, moisturizing or expectations. For familial dysautonomia, kinetin is not a standard treatment, and care still centers on managing symptoms and preventing complications. Researchers are now developing more potent compounds based on kinetin, along with other approaches aimed at the same splicing problem. Access to any of these is through clinical trials.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Kinetin, what you've noticed, or ask the community a question.